Lupin share price

Lupin stock gains 4% on USFDA approval for Rivaroxaban oral suspension; more details

Oct 01, 2025, 10:33 AM IST

On Wednesday, Lupin shares climbed as much as 3.9 per cent to touch a day’s high of Rs 1,984.90 on the BSE, up from Tuesday’s close of Rs 1,910.15.

Lupin shares in focus as arm buys VISUfarma for Rs 1,970 crore

Sep 29, 2025, 08:30 AM IST

Lupin share price: VISUfarma has a portfolio of more than 60 branded ophthalmology products and established operations across Italy, the UK, Spain, Germany and France.

Trump tariff impact: Gland Pharma, Zydus, Aurobindo shares fall up to 4%; analyst views

Sep 26, 2025, 09:22 AM IST

Gland Pharma dropped 4.03 per cent to open at Rs 1,892.50. Zydus Life fell 3.54 per cent to open at Rs 990.55. Natco Pharma slipped 2.7 per cent, Aurobindo Pharma declined 2.45 per cent

Pharma tariff: Aurobindo, Lupin, DRL, Sun, Zydus, Biocon in focus after 100% Trump tariff

Sep 26, 2025, 07:51 AM IST

Trump tariff: US exports as percentage of Biocon's sales stands at 46 per cent. Cipla (29 per cent), Dr Reddy's Labs (46 p cent), Lupin (36 per cent) and Sun Pharma (33 per cent), are other pharma exporters to the US.

Lupin shares rise 2% on US FDA approval for HIV drug; stock up 12 times in 15 sessions

Sep 25, 2025, 11:59 AM IST

By 11:33 am, the stock was trading 1.19 per cent higher at Rs 2,014.90, giving the company a market capitalisation of Rs 92,031 crore.

Lupin, Cochin Shipyard, Apeejay Surrendra: How to trade these 3 buzzing stocks

Sep 16, 2025, 07:25 AM IST

Brokerage firm SMIFS said that Apeejay Surrendra Park Hotels is attempting a breakout from symmetrical triangle formation, supported by a rising daily trendline.

Mazagon Dock, Bajaj Finance, Lupin: 3 stock picks by Axis Securities for short term gains

Sep 15, 2025, 11:49 AM IST

Axis Securities said that found support at its medium-term upward sloping trendline and staged a sharp rebound, signalling a potential reversal.

Lupin stock gains after pharma major carves out consumer healthcare unit

Jul 01, 2025, 03:58 PM IST

The move is part of Lupin's broader strategy to create a specialised consumer healthcare entity, particularly aimed at capitalising on India's burgeoning self-care market.

Lupin shares: Brokerage sees 23% upside potential, anticipates high growth with new US launches

May 16, 2025, 10:44 AM IST

Lupin has guided for a quarterly base revenue of $250 million from its US operations, bolstered by the upcoming launches of generic versions of gJynarque and gXarelto.

Aurobindo, Sun Pharma, other pharma stocks in focus after 90-day Trump tariff pause

Apr 10, 2025, 10:02 AM IST

Aurobindo Pharma and Gland Pharma have fallen 9 per cent each in the past one week and 22-23 per cent in 2025 so far. Glenmark Pharma is down 9 per cent for the week month period and 14 per cent year-to-date.

Pharma stocks crack up to 10% as Trump warns of 'never seen before' tariffs

Apr 04, 2025, 12:01 PM IST

Granules India, Lupin, Gland Pharma and Cipla fell 5-6 per cent. Sun Pharmaceutical Industries slipped 5 per cent while Dr Reddy's Labs was down 4 per cent.